CoChat
Sign Up
Cited by 90Neuroinflammation and Neurodegeneration MechanismsMicroRNA in disease regulationNeurological Disease Mechanisms and Treatments

MiR-124 and the Underlying Therapeutic Promise of Neurodegenerative Disorders

Open access
Han, Dong, Dong, Xiaoyu, Zheng, Dongming, Nao, Jianfei·2020·Frontiers in Pharmacology
DOI 10.3389/fphar.2019.01555PMC PMC6978711
Open this paper in CoChat — free accountOpen PDF

Abstract

Neurodegenerative disorders (NDDs) are a group of chronic progressive neurological diseases based on primary neurodegeneration. The common pathological characteristics of various NDDs are neuronal degeneration, deletion, glial cell proliferation, and hypertrophy at specific locations in the nervous system. Proliferation and hypertrophy of microglia are manifestations of inflammation. MicroRNAs (miRNAs) have emerged as pivotal regulators of glial cells. MiRNAs are small non-coding molecules that regulate gene expression. Altered expression of miRNAs has been associated with several NDD pathological processes, among which regulation of the inflammatory response is key and a research hotspot at present. At the same time, miRNAs are also biological markers for diagnosis and potential targets for treating NDDs. MiR-124 is highly conserved and enriched in the mammalian brain. Emerging studies have suggested that miR-124 is closely related to the pathogenesis of NDDs and may be an effective treatment strategy to reduce inflammation associated with NDDs. In this review, we describe a summary of general miRNA biology, implications in pathophysiology, the potential roles of miR-124 associated with inflammation, and the use of miRNA as a future biomarker and an application for NDD therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2019.01555

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Neuronal miRNAs, including miR-132-3p, the miR-29 family, miR-107, miR-124-3p, and miR-219-5p, play critical roles in coordinating amyloid processing, tau phosphorylation, synaptic integrity, and mitochondrial stability in AD.

    “Neuronal miRNAs, including miR-132-3p, the miR-29 family, miR-107, miR-124-3p, miR-219-5p (shared with oligodendrocytes), play critical roles in coordinating amyloid processing, tau phosphorylation, synaptic integrity, and mitochondrial stability in AD (Han et al., 2020; Hébert et al., 2008; Li et al., 2018; Salta et al., 2016; Walgrave et al., 2021a; Wang et al., 2008).”

    From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Han et al., 2020

    The “MiR-124 in Neurodegenerative Disorders” section (page unavailable) links miR-124 to APP processing, amyloid production, synaptic transmission, and plasticity in AD; it also reports that miR-124-3p attenuates tau hyperphosphorylation in vitro. The cited passages do not establish the claimed AD roles for the other listed miRNAs or a role in mitochondrial stability. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • Dysregulation of miR-124 is closely related to the development and progression of neurodegenerative diseases.

    “Its dysregulation is closely related to the development and progression of neurodegenerative diseases [166].”

    From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [166]

  • miR-124-3p is consistently reduced in AD models, and restoring its expression improves neuronal survival and synaptic integrity.

    “In AD models, miR-124-3p is consistently reduced, and restoring its expression improves neuronal survival and synaptic integrity (Han et al., 2020).”

    From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Han et al., 2020

  • miR-124 plays key roles in neurogenesis, synaptic strength and transmission, and glia-neuronal interactions essential for brain homeostasis.

    “MiR-124 is a brain-enriched miRNA that plays key roles in neurogenesis, synaptic strength and transmission, and glia-neuronal interactions essential for the maintenance of brain homeostasis (Sun et al., 2015; Han et al., 2019).”

    From Engineered Extracellular Vesicles Loaded With miR-124 Attenuate Cocaine-Mediated Activation of Microglia (2020) · cites this paper as Han et al., 2019

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 88

  1. Aalaei-Andabili S. H. Rezaei N. (2016). MicroRNAs (MiRs) Precisely Regulate Immune System Development and Function in Immunosenescence Process. Int. Rev. Immunol. 35, 57– 66. 10.3109/08830185.2015.1077828 26327579 · DOI
  2. Abu Lila A. S. Ishida T. (2017). Liposomal Delivery Systems: Design Optimization and Current Applications. Biol. Pharm. Bull. 40, 1– 10. 10.1248/bpb.b16-00624 28049940 · DOI
  3. Akerblom M. Jakobsson J. (2014). MicroRNAs as Neuronal Fate Determinants. Neuroscientist 20, 235– 242. 10.1177/1073858413497265 23877999 · DOI
  4. Brites D. Vaz A. R. (2014). Microglia centered pathogenesis in ALS: insights in cell interconnectivity. Front. Cell Neurosci. 8, 117. 10.3389/fncel.2014.00117 24904276 PMC4033073 · DOI
  5. Brown R.a.M. Richardson K. L. Kalinowski F. C. Epis M. R. Horsham J. L. Kabir T. D. (2018). Evaluation of MicroRNA Delivery In Vivo. Methods Mol. Biol. 1699, 155– 178. 10.1007/978-1-4939-7435-1_12 29086376 · DOI
  6. Cai C. Xie Y. Wu L. Chen X. Liu H. Zhou Y. (2017). PLGA-based dual targeted nanoparticles enhance miRNA transfection efficiency in hepatic carcinoma. Sci. Rep. 7, 46250. 10.1038/srep46250 28387375 PMC5384185 · DOI
  7. Caldeira C. Oliveira A. F. Cunha C. Vaz A. R. Falcao A. S. Fernandes A. (2014). Microglia change from a reactive to an age-like phenotype with the time in culture. Front. Cell Neurosci. 8, 152. 10.3389/fncel.2014.00152 24917789 PMC4040822 · DOI · Paper page
  8. Cao H. Yu W. Li X. Wang J. Gao S. Holton N. E. (2016). A new plasmid-based microRNA inhibitor system that inhibits microRNA families in transgenic mice and cells: a potential new therapeutic reagent. Gene Ther. 23, 527– 542. 10.1038/gt.2016.22 26934100 PMC4891277 · DOI
  9. Chen W. W. Zhang X. Huang W. J. (2016). Role of neuroinflammation in neurodegenerative diseases (Review). Mol. Med. Rep. 13, 3391– 3396. 10.3892/mmr.2016.4948 26935478 PMC4805095 · DOI
  10. Cheng L. C. Pastrana E. Tavazoie M. Doetsch F. (2009). miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat. Neurosci. 12, 399– 408. 10.1038/nn.2294 19287386 PMC2766245 · DOI · Paper page
  11. Chhor V. Le Charpentier T. Lebon S. Ore M. V. Celador I. L. Josserand J. (2013). Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav. Immun. 32, 70– 85. 10.1016/j.bbi.2013.02.005 23454862 PMC3694309 · DOI
  12. Cianciulli A. Dragone T. Calvello R. Porro C. Trotta T. Lofrumento D. D. (2015). IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. Int. Immunopharmacol. 24, 369– 376. 10.1016/j.intimp.2014.12.035 25576658 · DOI
  13. Colonna M. Butovsky O. (2017). Microglia Function in the Central Nervous?System During Health and Neurodegeneration. Annu. Rev. Immunol. 35, 441– 468. 10.1146/annurev-immunol-051116-052358 28226226 PMC8167938 · DOI · Paper page
  14. Coolen M. Katz S. Bally-Cuif L. (2013). miR-9: a versatile regulator of neurogenesis. Front. Cell Neurosci. 7, 220. 10.3389/fncel.2013.00220 24312010 PMC3834235 · DOI · Paper page
  15. Cunha C. Santos C. Gomes C. Fernandes A. Correia A. M. Sebastiao A. M. (2018). Downregulated Glia Interplay and Increased miRNA-155 as?Promising Markers to Track ALS at an Early Stage. Mol. Neurobiol. 55, 4207– 4224. 10.1007/s12035-017-0631-2 28612258 · DOI
  16. D’ambrosi N. Finocchi P. Apolloni S. Cozzolino M. Ferri A. Padovano V. (2009). The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J. Immunol. 183, 4648– 4656. 10.4049/jimmunol.0901212 19734218 · DOI · Paper page
  17. Devulapally R. Paulmurugan R. (2014). Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 6, 40– 60. 10.1002/wnan.1242 23996830 PMC3865230 · DOI
  18. Dong R. F. Zhang B. Tai L. W. Liu H. M. Shi F. K. Liu N. N. (2018). The neuroprotective role of MiR-124-3p in a 6-hydroxydopamine-induced cell model of Parkinson’s disease via the regulation of ANAX5. J. Cell Biochem. 119, 269– 277. 10.1002/jcb.26170 28543594 · DOI · Paper page
  19. Fan Z. Aman Y. Ahmed I. Chetelat G. Landeau B. Ray Chaudhuri K. (2015). Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia. Alzheimers Dement. 11, 608– 621.e607. 10.1016/j.jalz.2014.06.016 25239737 · DOI · Paper page
  20. Fang M. Wang J. Zhang X. Geng Y. Hu Z. Rudd J. A. (2012). The miR-124 regulates the expression of BACE1/beta-secretase correlated with cell death in Alzheimer’s disease. Toxicol. Lett. 209, 94– 105. 10.1016/j.toxlet.2011.11.032 22178568 · DOI
  21. Fischbach S. J. Carew T. J. (2009). MicroRNAs in memory processing. Neuron 63, 714– 716. 19778498
  22. Fornaguera C. Dols-Perez A. Caldero G. Garcia-Celma M. J. Camarasa J. Solans C. (2015). PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier. J. Control Release 211, 134– 143. 10.1016/j.jconrel.2015.06.002 26057857 · DOI
  23. Franco R. Fernandez-Suarez D. (2015). Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 131, 65– 86. 10.1016/j.pneurobio.2015.05.003 26067058 · DOI
  24. Frank-Cannon T. C. Alto L. T. Mcalpine F. E. Tansey M. G. (2009). Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener. 4, 47. 10.1186/1750-1326-4-47 19917131 PMC2784760 · DOI · Paper page
  25. Gerhard A. Pavese N. Hotton G. Turkheimer F. Es M. Hammers A. (2006). In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol. Dis. 21, 404– 412. 10.1016/j.nbd.2005.08.002 16182554 · DOI · Paper page
  26. Gitler A. D. Dhillon P. Shorter J. (2017). Neurodegenerative disease: models, mechanisms, and a new hope. Dis. Model Mech. 10, 499– 502. 10.1242/dmm.030205 28468935 PMC5451177 · DOI
  27. Golko-Perez S. Mandel S. Amit T. Kupershmidt L. Youdim M. B. Weinreb O. (2016). Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis. Neurotox. Res. 29, 208– 217. 10.1007/s12640-015-9574-4 26581376 · DOI
  28. Gong X. Wang H. Ye Y. Shu Y. Deng Y. He X. (2016). miR-124 regulates cell apoptosis and autophagy in dopaminergic neurons and protects them by regulating AMPK/mTOR pathway in Parkinson’s disease. Am. J. Transl. Res. 8, 2127– 2137. 27347320 PMC4891425
  29. Graber D. J. Hickey W. F. Harris B. T. (2010). Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J. Neuroinflammation 7, 8. 10.1186/1742-2094-7-8 20109233 PMC2825214 · DOI
  30. Gu X. L. Long C. X. Sun L. Xie C. Lin X. Cai H. (2010). Astrocytic expression of Parkinson’s disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol. Brain 3, 12. 10.1186/1756-6606-3-12 20409326 PMC2873589 · DOI
  31. He Y. Wang Z. J. (2012). Let-7 microRNAs and Opioid Tolerance. Front. Genet. 3, 110. 10.3389/fgene.2012.00110 22737161 PMC3380223 · DOI
  32. Hobel S. Aigner A. (2013). Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5, 484– 501. 10.1002/wnan.1228 23720168 · DOI
  33. Hsu S. H. Yu B. Wang X. Lu Y. Schmidt C. R. Lee R. J. (2013). Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine 9, 1169– 1180. 10.1016/j.nano.2013.05.007 23727126 PMC3815988 · DOI
  34. Hugon J. Paquet C. (2008). Targeting miRNAs in Alzheimer’s disease. Expert Rev. Neurother. 8, 1615– 1616. 10.1586/14737175.8.11.1615 18986230 · DOI
  35. Itaka K. Kataoka K. (2009). Recent development of nonviral gene delivery systems with virus-like structures and mechanisms. Eur. J. Pharm. Biopharm. 71, 475– 483. 10.1016/j.ejpb.2008.09.019 18955136 · DOI
  36. Jiang H. Liu C. X. Feng J. B. Wang P. Zhao C. P. Xie Z. H. (2010). Granulocyte colony-stimulating factor attenuates chronic neuroinflammation in the brain of amyloid precursor protein transgenic mice: an Alzheimer’s disease mouse model. J. Int. Med. Res. 38, 1305– 1312. 10.1177/147323001003800412 20926003 · DOI
  37. Johnson R. Buckley N. J. (2009). Gene dysregulation in Huntington’s disease: REST, microRNAs and beyond. Neuromol. Med. 11, 183– 199. 10.1007/s12017-009-8063-4 19458943 · DOI
  38. Johnson R. Teh C. H. Kunarso G. Wong K. Y. Srinivasan G. Cooper M. L. (2008). REST regulates distinct transcriptional networks in embryonic and neural stem cells. PloS Biol. 6, e256. 10.1371/journal.pbio.0060256 18959480 PMC2573930 · DOI
  39. Kanagaraj N. Beiping H. Dheen S. T. Tay S. S. (2014). Downregulation of miR-124 in MPTP-treated mouse model of Parkinson’s disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins. Neuroscience 272, 167– 179. 10.1016/j.neuroscience.2014.04.039 24792712 · DOI · Paper page
  40. Keizman D. Rogowski O. Berliner S. Ish-Shalom M. Maimon N. Nefussy B. (2009). Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 119, 383– 389. 10.1111/j.1600-0404.2008.01112.x 18976328 · DOI
  41. Khandelwal N. Dey S. K. Chakravarty S. Kumar A. (2019). miR-30 Family miRNAs Mediate the Effect of Chronic Social Defeat Stress on Hippocampal Neurogenesis in Mouse Depression Model. Front. Mol. Neurosci. 12, 188. 10.3389/fnmol.2019.00188 31440139 PMC6694739 · DOI
  42. Kim Y. S. Choi D. H. Block M. L. Lorenzl S. Yang L. Kim Y. J. (2007). A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J. 21, 179– 187. 10.1096/fj.06-5865com 17116747 · DOI
  43. Labatut A. E. Mattheolabakis G. (2018). Non-viral based miR delivery and recent developments. Eur. J. Pharm. Biopharm. 128, 82– 90. 10.1016/j.ejpb.2018.04.018 29679644 PMC5984722 · DOI
  44. Lagos-Quintana M. Rauhut R. Yalcin A. Meyer J. Lendeckel W. Tuschl T. (2002). Identification of tissue-specific microRNAs from mouse. Curr. Biol. 12, 735– 739. 10.1016/s0960-9822(02)00809-6 12007417 · DOI · Paper page
  45. Lee S. T. Im W. Ban J. J. Lee M. Jung K. H. Lee S. K. (2017). Exosome-Based Delivery of miR-124 in a Huntington’s Disease Model. J. Mov. Disord. 10, 45– 52. 10.14802/jmd.16054 28122430 PMC5288667 · DOI · Paper page
  46. Li Q. Barres B. A. (2018). Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 18, 225– 242. 10.1038/nri.2017.125 29151590 · DOI · Paper page
  47. Li A. D. Tong L. Xu N. Ye Y. Nie P. Y. Wang Z. Y. (2019). miR-124 regulates cerebromicrovascular function in APP/PS1 transgenic mice via C1ql3. Brain Res. Bull. 153, 214– 222. 10.1016/j.brainresbull.2019.09.002 31499089 · DOI
  48. Lopez-Ramirez M. A. Nicoli S. (2014). Role of miRNAs and epigenetics in neural stem cell fate determination. Epigenetics 9, 90– 100. 10.4161/epi.27536 24342893 PMC3928190 · DOI
  49. Ma X. X. Ma Z. Pan Q. (2018). The Challenges of Long-Term Transcriptional Gene Silencing by RNA Viruses. Trends Biochem. Sci. 43, 649– 650. 10.1016/j.tibs.2018.06.010 30041840 · DOI
  50. Malik S. Bahal R. (2019). Investigation of PLGA nanoparticles in conjunction with nuclear localization sequence for enhanced delivery of antimiR phosphorothioates in cancer cells in vitro. J. Nanobiotechnol. 17, 57. 10.1186/s12951-019-0490-2 PMC6475967 31010426 · DOI
  51. Marcuzzo S. Kapetis D. Mantegazza R. Baggi F. Bonanno S. Barzago C. (2014). Altered miRNA expression is associated with neuronal fate in G93A-SOD1 ependymal stem progenitor cells. Exp. Neurol. 253, 91– 101. 10.1016/j.expneurol.2013.12.007 24365539 · DOI
  52. McKenzie J. A. Spielman L. J. Pointer C. B. Lowry J. R. Bajwa E. Lee C. W. (2017). Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases. Curr. Aging Sci. 10, 158– 176. 10.2174/1874609810666170315113244 28302047 · DOI
  53. Medeiros R. Figueiredo C. P. Pandolfo P. Duarte F. S. Prediger R. D. Passos G. F. (2010). The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behav. Brain Res. 209, 165– 173. 10.1016/j.bbr.2010.01.040 20122965 · DOI · Paper page
  54. Mishima T. Mizuguchi Y. Kawahigashi Y. Takizawa T. Takizawa T. (2007). RT-PCR-based analysis of microRNA (miR-1 and -124) expression in mouse CNS. Brain Res. 1131, 37– 43. 10.1016/j.brainres.2006.11.035 17182009 · DOI · Paper page
  55. Njie E. G. Boelen E. Stassen F. R. Steinbusch H. W. Borchelt D. R. Streit W. J. (2012). Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function. Neurobiol. Aging 33, 195.e1–12. 10.1016/j.neurobiolaging.2010.05.008 PMC4162517 20580465 · DOI · Paper page
  56. Obeid M. A. Al Qaraghuli M. M. Alsaadi M. Alzahrani A. R. Niwasabutra K. Ferro V. A. (2017). Delivering natural products and biotherapeutics to improve drug efficacy. Ther. Delivery 8, 947– 956. 10.4155/tde-2017-0060 29061102 · DOI
  57. Pinto S. Cunha C. Barbosa M. Vaz A. R. Brites D. (2017). Exosomes from NSC-34 cells transfected with hSOD1-G93A are enriched in miR-124 and drive alterations in microglia phenotype. Front. Neurosci. 11, 273. 10.3389/fnins.2017.00273 28567000 PMC5434170 · DOI · Paper page
  58. Politis M. Lahiri N. Niccolini F. Su P. Wu K. Giannetti P. (2015). Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington’s disease gene carriers. Neurobiol. Dis. 83, 115– 121. 10.1016/j.nbd.2015.08.011 26297319 · DOI
  59. Ridolfi B. Abdel-Haq H. (2017). Neurodegenerative Disorders Treatment: The MicroRNA Role. Curr. Gene Ther. 17, 327– 363. 10.2174/1566523218666180119120726 29357791 · DOI
  60. Ross C. A. Tabrizi S. J. (2011). Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83– 98. 10.1016/s1474-4422(10)70245-3 21163446 · DOI
  61. Sadlon A. Takousis P. Alexopoulos P. Evangelou E. Prokopenko I. Perneczky R. (2019). miRNAs Identify Shared Pathways in Alzheimer’s and Parkinson’s Diseases. Trends Mol. Med. 25, 662– 672. 10.1016/j.molmed.2019.05.006 31221572 · DOI
  62. Salminen A. Ojala J. Kauppinen A. Kaarniranta K. Suuronen T. (2009). Inflammation in Alzheimer’s disease: amyloid-beta oligomers trigger innate?immunity defence via pattern recognition receptors. Prog. Neurobiol. 87, 181– 194. 10.1016/j.pneurobio.2009.01.001 19388207 · DOI
  63. Salter M. W. Stevens B. (2017). Microglia emerge as central players in brain disease. Nat. Med. 23, 1018– 1027. 10.1038/nm.4397 28886007 · DOI · Paper page
  64. Saraiva C. Ferreira L. Bernardino L. (2016). Traceable microRNA-124 loaded nanoparticles as a new promising therapeutic tool for Parkinson’s disease. Neurogenesis (Austin) 3, e1256855. 28405588 PMC5384609
  65. Saraiva C. Esteves M. Bernardino L. (2017). MicroRNA: Basic concepts and implications for regeneration and repair of neurodegenerative diseases. Biochem. Pharmacol. 141, 118– 131. 10.1016/j.bcp.2017.07.008 28709951 · DOI
  66. Sargsyan S. A. Monk P. N. Shaw P. J. (2005). Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 51, 241– 253. 10.1002/glia.20210 15846792 · DOI
  67. Sasidharan V. Marepally S. Elliott S. A. Baid S. Lakshmanan V. Nayyar N. (2017). The miR-124 family of microRNAs is crucial for regeneration of the brain and visual system in the planarian Schmidtea mediterranea. Development 144, 3211– 3223. 10.1242/dev.144758 28807895 PMC5612250 · DOI
  68. Schain M. Kreisl W. C. (2017). Neuroinflammation in Neurodegenerative Disorders-a Review. Curr. Neurol. Neurosci. Rep. 17, 25. 10.1007/s11910-017-0733-2 28283959 · DOI · Paper page
  69. Shabestari Khiabani S. Farshbaf M. Akbarzadeh A. Davaran S. (2017). Magnetic nanoparticles: preparation methods, applications in cancer diagnosis and cancer therapy. Artif. Cells Nanomed. Biotechnol. 45, 6– 17. 10.3109/21691401.2016.1167704 27050642 · DOI
  70. Smith P. Al Hashimi A. Girard J. Delay C. Hebert S. S. (2011). In vivo regulation of amyloid precursor protein neuronal splicing by microRNAs. J. Neurochem. 116, 240– 247. 10.1111/j.1471-4159.2010.07097.x 21062284 · DOI
  71. Soreq H. Wolf Y. (2011). NeurimmiRs: microRNAs in the neuroimmune interface. Trends Mol. Med. 17, 548– 555. 10.1016/j.molmed.2011.06.009 21813326 · DOI
  72. Szelenberger R. Kacprzak M. Saluk-Bijak J. Zielinska M. Bijak M. (2019). Plasma MicroRNA as a novel diagnostic. Clin. Chim. Acta 499, 98– 107. 10.1016/j.cca.2019.09.005 31499022 · DOI
  73. Tang Y. Le W. (2016). Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases. Mol. Neurobiol. 53, 1181– 1194. 10.1007/s12035-014-9070-5 25598354 · DOI · Paper page
  74. Tansey M. G. Goldberg M. S. (2010). Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510– 518. 10.1016/j.nbd.2009.11.004 19913097 PMC2823829 · DOI · Paper page
  75. Tapeinos C. Battaglini M. Ciofani G. (2017). Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control Release 264, 306– 332. 10.1016/j.jconrel.2017.08.033 28844756 PMC6701993 · DOI
  76. Torrisi L. (2015). Gold nanoparticles enhancing protontherapy efficiency. Recent Pat. Nanotechnol. 9, 51– 60. 10.2174/1872210509999141222224121 25986229 · DOI
  77. Villela D. Ramalho R. F. Silva A. R. Brentani H. Suemoto C. K. Pasqualucci C. A. (2016). Differential DNA Methylation of MicroRNA Genes in Temporal Cortex from Alzheimer’s Disease Individuals. Neural Plast 2016, 2584940. 10.1155/2016/2584940 27213057 PMC4861808 · DOI
  78. Wang J. Wu X. Wang C. Rong Z. Ding H. Li H. (2016). Facile Synthesis of Au-Coated Magnetic Nanoparticles and Their Application in Bacteria Detection via a SERS Method. ACS Appl. Mater Interfaces 8, 19958– 19967. 10.1021/acsami.6b07528 27420923 · DOI
  79. Wang X. Liu D. Huang H. Z. Wang Z. H. Hou T. Y. Yang X. (2018). A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer’s Disease. Biol. Psychiatry 83, 395– 405. 10.1016/j.biopsych.2017.07.023 28965984 · DOI
  80. Wojtera M. Sobow T. Kloszewska I. Liberski P. P. Brown D. R. Sikorska B. (2012). Expression of immunohistochemical markers on microglia in Creutzfeldt-Jakob disease and Alzheimer’s disease: morphometric study and review of the literature. Folia Neuropathol. 50, 74– 84. 22505366
  81. Yao L. Ye Y. Mao H. Lu F. He X. Lu G. (2018). MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J. Neuroinflammation 15, 13. 10.1186/s12974-018-1053-4 29329581 PMC5767033 · DOI
  82. Yao L. Zhu Z. Wu J. Zhang Y. Zhang H. Sun X. (2019). MicroRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson’s disease. Faseb j 33, 8648– 8665. 10.1096/fj.201900363R 30995872 · DOI
  83. Yin H. Kanasty R. L. Eltoukhy A. A. Vegas A. J. Dorkin J. R. Anderson D. G. (2014). Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541– 555. 10.1038/nrg3763 25022906 · DOI · Paper page
  84. Yoon H. Y. Jeon S. You D. G. Park J. H. Kwon I. C. Koo H. (2017). Inorganic Nanoparticles for Image-Guided Therapy. Bioconjug Chem. 28, 124– 134. 10.1021/acs.bioconjchem.6b00512 27788580 · DOI
  85. Yu C. Zhang X. Sun X. Long C. Sun F. Liu J. (2018). Ketoprofen and MicroRNA-124 Co-loaded poly (lactic-co-glycolic acid) microspheres inhibit progression of Adjuvant-induced arthritis in rats. Int. J. Pharm. 552, 148– 153. 10.1016/j.ijpharm.2018.09.063 30268854 · DOI
  86. Zetterberg H. Burnham S. C. (2019). Blood-based molecular biomarkers for Alzheimer’s disease. Mol. Brain 12, 26. 10.1186/s13041-019-0448-1 30922367 PMC6437931 · DOI
  87. Zhou F. Zhang C. Guan Y. Chen Y. Lu Q. Jie L. (2018). Screening the expression characteristics of several miRNAs in G93A-SOD1 transgenic mouse: altered expression of miRNA-124 is associated with astrocyte differentiation by targeting Sox2 and Sox9. J. Neurochem. 145, 51– 67. 28960306
  88. Zhou Y. Deng J. Chu X. Zhao Y. Guo Y. (2019). Role of Post-Transcriptional Control of Calpain by miR-124-3p in the Development of Alzheimer’s Disease. J. Alzheimers Dis. 67, 571– 581. 10.3233/jad-181053 30584150 · DOI · Paper page

Cited by

Sorted by citations

Authors
Han, D., Dong, X., Zheng, D., & Nao, J.
Affiliations
Sheng Jing Hospital (CN)
Corresponding author
Nao, Jianfei
ORCID
Venue
Frontiers in Pharmacology
Publisher
Frontiers Media SA
Published
2020-01-17
Volume
10
Pages
1555-1555
ISSN
1663-9812 (ISSN-L)
DOI
10.3389/fphar.2019.01555
PMC
PMC6978711
OpenAlex
W2993255485
Cited by
90
References
10
Citations by year
2026: 10 · 2025: 21 · 2024: 19 · 2023: 11 · 2022: 14 · 2021: 11 · 2020: 2 · 2018: 2
FWCI
0.95
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
miR-124, microRNA, neurodegenerative diseases, neuroinflammation, microglial proliferation, glial cells, biomarkers, therapeutic target, neurodegeneration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review